Clinical Outcomes of Lisocabtagene Maraleucel (liso-cel) in Younger Patients (Pts) with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL)
Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Sairah Ahmed, Iris Isufi(Yale University), Bradley D. Hunter(Intermountain Healthcare), Jennifer L. Crombie(Dana-Farber Cancer Institute), Debasmita Roy(Bristol-Myers Squibb (United States)), Prachi Ghodke(Syneos Health (India)), Krish Patel, Matthew Frigault(Massachusetts General Hospital), Miguel-Angel Perales(Memorial Sloan Kettering Cancer Center), Matthew A. Lunning, Marcelo C. Pasquini(Medical College of Wisconsin), David Bernasconi(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
|The Lancet Rheumatology|2020|309
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
|Blood|2019|187
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
|Blood|2024|132
The treatment of Burkitt lymphoma in adults
|Blood|2020|105